News

High Non-Relapse Mortality Remains Barrier to Allogeneic Transplantation Success Rates for Patients With Myelofibrosis

01/14/2026

Emily Estrada

Among patients with myelofibrosis undergoing allogeneic transplantation, improved outcomes and long-term survival remain limited by high non-relapse mortality.

Among patients with...

01/14/2026

Oncology

News

Pacritinib Therapy Shows Improved Symptom Reduction and Spleen Response for Patients With Myelofibrosis and Thrombocytopenia

01/14/2026

Emily Estrada

Pacritinib therapy showed meaningful clinical benefit, including spleen size reduction, symptom improvement, and hematologic response regardless of the line of therapy, according to a real-world analysis of patients with myelofibrosis and...

Pacritinib therapy showed...

01/14/2026

Oncology

Conference Coverage

Elritercept Plus Ruxolitinib Demonstrates Favorable Safety and Strong Efficacy for Patients With Myelofibrosis and Anemia: RESTORE Trial

01/14/2026

Ciro Rinaldi, MD, PhD

Ciro Rinaldi, MD, PhD, shared results from the phase 2 RESTORE trial, which evaluated the combination of elritercept and ruxolitinib among patients with myelofibrosis and anemia who were resistant or intolerant to ruxolitinib alone.

Ciro Rinaldi, MD, PhD, shared...

01/14/2026

Oncology

Conference Coverage

Rusfertide Demonstrates Durable Hematocrit Control and Symptom Improvement for Polycythemia Vera: VERIFY Trial

12/17/2025

Andrew Kuykendall

At the 2025 ASH Annual Meeting & Exposition, Andrew Kuykendall, MD, discussed updated results from the phase 3 VERIFY trial which evaluated rusfertide among patients with polycythemia vera.

At the 2025 ASH Annual Meeting &...

12/17/2025

Oncology

News

Ruxolitinib Therapy for Myelofibrosis Demonstrates Comparable Efficacy and Safety Among All Patient Age Groups

12/01/2025

Emily Estrada

According to a retrospective analysis, ruxolitinib therapy for patients with myelofibrosis demonstrated comparable efficacy across all age groups.

According to a retrospective...

12/01/2025

Oncology

News

Rovadicitinib Shows Efficacy and Manageable Safety for Ruxolitinib-Resistant or Intolerant Myelofibrosis

10/28/2025

Emily Estrada

Among patients with myelofibrosis refractory or intolerant to ruxolitinib, the JAK/ROCK inhibitor rovadicitinib demonstrated promising clinical activity and safety in early clinical trials.

Among patients with...

10/28/2025

Oncology

Videos

Pelabresib Plus Ruxolitinib Demonstrates Deep Clinical Responses for Patients With Myelofibrosis: MANIFEST-2 Trial

09/26/2025

Claire Harrison, MD

Claire Harrison, MD, shares results from the phase 3 MANIFEST-2 evaluating the clinical efficacy of pelabresib combined with ruxolitinib compared with ruxolitinib alone for patients with myelofibrosis naïve to JAK inhibitor therapy.

Claire Harrison, MD, shares...

09/26/2025

Oncology

Conference Coverage

Pacritinib Therapy May Improve Hemoglobin Responses Among Patients With Myelofibrosis

09/03/2025

Raajit Rampal, MD, PhD

Raajit Rampal, MD, PhD shares results from a real-world analysis evaluating outcomes and hemoglobin responses among patients with myelofibrosis who were treated with pacritinib.

Raajit Rampal, MD, PhD shares...

09/03/2025

Oncology

Conference Coverage

BET Inhibitor INCB057643 Shows Promising Efficacy for Treatment of Relapsed/Refractory Myelofibrosis

07/14/2025

Emily Estrada

The small-molecular BET inhibitor, INCB057643, demonstrated clinical activity and manageable safety among patients with relapsed/refractory myelofibrosis.

The small-molecular BET...

07/14/2025

Oncology

Conference Coverage

BET Inhibitor INCB057643 Shows Promising Efficacy for Treatment of Relapsed/Refractory Myelofibrosis

07/14/2025

Emily Estrada

The small-molecular BET inhibitor, INCB057643, demonstrated clinical activity and manageable safety among patients with relapsed/refractory myelofibrosis.

The small-molecular BET...

07/14/2025

Oncology

Recent News

News

Incidence of Cutaneous Squamous Cell Carcinoma and Carcinoma in Situ Continues to Rise

01/29/2026

Stephanie Holland

Results from a real-world analysis have demonstrated that the incidence of cutaneous squamous cell carcinoma and cutaneous squamous cell carcinoma in situ has steadily increased over the past 2 decades, emphasizing the need for monitoring...

Results from a real-world...

01/29/2026

Oncology

News

Elenagen Plus Gemcitabine Improves Overall Survival for Patients With Platinum-Resistant Ovarian Cancer

01/29/2026

Emily Estrada

The addition of elenagen to gemcitabine therapy significantly prolonged overall survival among patients with platinum-resistant ovarian cancer without increasing toxicity, according to results from a phase 2 trial.

The addition of elenagen to...

01/29/2026

Oncology

News

Axicabtagene Ciloleucel Plus Atezolizumab Demonstrates Promise in Relapsed/Refractory Large B-Cell Lymphoma

01/28/2026

Stephanie Holland

Results from the phase 1/2 ZUMA-6 trial showed that the addition of atezolizumab to axicabtagene ciloleucel showed promising clinical activity among patients with relapsed or refractory large B-cell lymphoma.

Results from the phase 1/2...

01/28/2026

Oncology

News

Advances in Antibody-Based Therapies for the Treatment of Relapsed Small-Cell Lung Cancer

01/27/2026

Gina Tomaine

Antibody-based therapies are reshaping the treatment paradigm for relapsed SCLC by enabling antigen-specific targeting with clinically meaningful activity beyond traditional chemotherapy, according to findings from a comprehensive review.

Antibody-based therapies are...

01/27/2026

Oncology

News

Tucatinib Plus Trastuzumab Shows Durable Efficacy and Manageable Safety for HER2-Posititive Metastatic Colorectal Cancer: MOUNTAINEER Trial

01/27/2026

Emily Estrada

Tucatinib plus trastuzumab provided durable responses and a favorable safety profile among patients with chemotherapy-refractory, HER2positive metastatic colorectal cancer, based on results from the phase 2 MOUNTAINEER trial.

Tucatinib plus trastuzumab...

01/27/2026

Oncology

News

TOMOX-Bevacizumab Combination Shows Feasibility as Second-Line Therapy in mCRC

01/27/2026

Emily Estrada

A TOMOX-bevacizumab combination demonstrated an acceptable safety profile as a second-line treatment for patients with metastatic colorectal cancer progressing after irinotecan-based chemotherapy, according to a phase 2 study.

A TOMOX-bevacizumab combination...

01/27/2026

Oncology

News

ISL1 Emerges as a Potential Predictive Biomarker for Efficacy of Lurbinectedin in Relapsed SCLC

01/27/2026

Gina Tomaine

A translational study identified ISL1 as a potential predictive biomarker in small cell lung cancer, defining a subtype with enhanced sensitivity to lurbinectedin and supporting biomarker-driven patient selection in future trials.

A translational study identified...

01/27/2026

Oncology

News

CSF-1-Targeted Therapies Continue to Redefine Systemic Treatment for TGCT

01/26/2026

Gina Tomaine

Systemic CSF-1R inhibition provides an effective option for unresectable or recurrent tenosynovial giant cell tumor, with safety and tolerability favoring newer agents and potentially shifting first-line treatment paradigms.

Systemic CSF-1R inhibition...

01/26/2026

Oncology

News

Sacituzumab Govitecan Plus Pembrolizumab Significantly Prolongs PFS in PD-L1-Positive Triple-Negative Breast Cancer

01/22/2026

Stephanie Holland

Results from the phase 3 ASCENT-04 trial demonstrate that sacituzumab govitecan plus pembrolizumab significantly prolongs PFS compared to pembrolizumab plus chemotherapy among previously untreated patients with advanced, PD-L1–positive...

Results from the phase 3...

01/22/2026

Oncology

News

Anbenitamab Plus Chemotherapy After Trastuzumab Failure in HER2-Positive G/GEJ Cancer

01/21/2026

Stephanie Holland

Results from a multicenter, phase 3 trial demonstrated that anbenitamab plus chemotherapy improved survival compared with placebo plus chemotherapy among previously treated patients with HER2-positive gastric or gastroesophageal junction...

Results from a multicenter,...

01/21/2026

Oncology